NCT06473961View on ClinicalTrials.gov

A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of NSCLC

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

July 1, 2027

Conditions
Non Small Cell Lung Cancer MetastaticNon Small Cell Lung Cancer
Interventions
BIOLOGICAL

Autologous Tumor Infiltrating Lymphocytes

A tumor sample is resected from each participant and cultured ex vivo to generate tumor infiltrating lymphocytes. After lymphodepletion, patients are infused GC101 TIL followed low-dose PD-1 antibody.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Juncell Therapeutics

INDUSTRY